Immunovant, Inc.

NASDAQ:IMVT

Biotechnology

Healthcare
$33.17 +2.00%

+$0.69 today

Market cap
$6.86B
Beta
0.79
P/E (TTM)
-14.3
EPS (TTM)
-$2.48
52W Low $14.32High $36.29

Volume 0.91M

Average 1.84M

IMVT Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Immunovant, Inc.NASDAQ: IMVT

Gross Margin · Q2 FY2027 · quarter ended Sep 2026

Gross margin not reported for Q2 FY2027

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
—— QoQ
Last fiscal yearMar 2026
—— YoY
LTMSep 2026
100.0%— YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

No Gross Margin data reported for this period type.

Gross Margin vs competitors

How IMVT compares with its peers on the latest reported figures

  • IMVT's LTM Sep 2026 gross margin of 100.0% is the 2nd highest of the 6 companies compared; the peer median is 99.3%.
IMVT Competitors Peer median
Gross Margin for IMVT and competitors
Company Period LTM level YoY 3-year change
ANABAnaptysBio, Inc.LTM Mar 2026116.4% +166.6 pp+862.2 pp
IMVTImmunovant, Inc.LTM Sep 2026100.0% ——
ZBIOZenas BioPharma, Inc.FY2025100.0% +2782.8 pp—
QTTBQ32 Bio Inc.LTM Mar 202699.3% —-0.7 pp
TGTXTG Therapeutics, Inc.LTM Sep 202682.7% -2.6 pp-6.8 pp
ACRSAclaris Therapeutics, Inc.LTM Mar 202676.3% +55.8 pp+13.5 pp
TRAXFirst Tracks Biotherapeutics IncFY2025— ——
CGEMCullinan Therapeutics, Inc.FY2025— ——
ANNXAnnexon, Inc.FY2025— ——
CABACabaletta Bio, Inc.FY2025— ——
IMUXImmunic, Inc.FY2025— ——
Peer median (excluding IMVT) 99.3%+111.2 pp+6.4 pp

Competitors are the stored peer set for IMVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development101.81M160.26M212.93M360.92M456.66M
Selling, General & Admin54.23M48.02M57.28M77.24M76.24M
Operating Expenses156.03M208.28M270.21M438.15M532.9M
Depreciation & Amortization126K193K231K377K409K
EBITDA(156.69M)(198.28M)(258.54M)(412.57M)(504.98M)
EBITDA Margin—————
Operating Income(156.03M)(208.28M)(270.21M)(438.15M)(532.9M)
Operating Margin—————
Interest Income07.58M24.95M24.73M25.33M
Interest Expense012.48M000
Other Income / Expenses(781K)(2.68M)11.44M25.2M27.51M
Income Before Tax(156.81M)(210.95M)(258.77M)(412.95M)(505.39M)
Pre-Tax Margin—————
Income Tax Expense(84K)9K567K891K215K
Net Income(156.73M)(210.96M)(259.34M)(413.84M)(505.61M)
Net Margin—————
EPS (Basic)(1.43)(1.71)(1.88)(2.73)(2.77)
EPS (Diluted)(1.43)(1.71)(1.88)(2.73)(2.77)
Weighted Avg Shares109.68M123.08M138.1M151.57M182.42M
Weighted Avg Shares (Diluted)109.68M123.08M138.1M151.57M182.42M

Immunovant, Inc.

NASDAQ:IMVT

Intrinsic Alpha fair value

Locked

Current Price

$33.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.